{"id":3415,"date":"2015-11-17T16:17:18","date_gmt":"2015-11-17T16:17:18","guid":{"rendered":"http:\/\/www.medic8.com\/news\/?p=3415"},"modified":"2015-11-17T16:17:59","modified_gmt":"2015-11-17T16:17:59","slug":"nice-claims-breast-cancer-drug-is-too-expensive-for-widespread-use-6049","status":"publish","type":"post","link":"https:\/\/www.medic8.com\/news\/nice-claims-breast-cancer-drug-is-too-expensive-for-widespread-use-6049\/","title":{"rendered":"NICE Claims Breast Cancer Drug is Too Expensive for Widespread Use-6049"},"content":{"rendered":"

A breast cancer<\/a> drug known\u00a0for extending\u00a0lives will not be routinely available on the NHS because it is too expensive. NICE (National Institute of\u00a0 Health Care and Excellence) has confirmed that Kadcyla, a drug\u00a0able to extend life expectancy by around six\u00a0months in patients with incurable breast cancer, will not be available for all suitable candidates in England and Wales because the price of the medication<\/a> is too high.<\/p>\n

The draft guidelines on the drug state that the current quote of \u00a390,000 per patient is too high to make the drug routinely available. NICE has criticised Roche, the manufacturer of Kadcyla, for making the fee too high. However, Roche has stated that negotiations are still ongoing and it may be possible to reach an agreement\u00a0that is\u00a0more satisfactory for the watchdog.<\/p>\n

Kadcyla can be prescribed for\u00a0women who have incurable HER2-positive breast cancer\u00a0that\u00a0has spread.\u00a0It is known to extend life expectancy by around six\u00a0months. The drug is available through the Cancer Drugs Fund, but is not currently available to all.<\/p>\n

Recently, NHS England agreed a discounted price for the drug with Swiss pharmaceutical firm Roche in order to take it off the Cancer Drugs Fund list. However, the discount was significantly smaller when NICE negotiated regular use of the drug across England and Wales and the new price was deemed too high. The drug is not routinely available in Scotland either.<\/p>\n

NICE\u2019s chief executive Sir Andrew Dillon said that he understands that Kadcyla has an important role to play in cases of incurable breast cancer, however the fee quoted by the manufacturer is too high to make the drug routinely available.<\/p>\n

Roche has responded to the comments, stating that a \u201cunified approach\u201d is required and insisting that negotiations have not yet come to an end.<\/p>\n

Dr Caitlin Barrand from the charity Breast Cancer Now described the news as \u201chugely disappointing\u201d and encouraged Prime Minister David Cameron to endeavour to bring costs down so that people who have incurable cancer are able to access the best possible treatments.<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

A breast cancer drug known\u00a0for extending\u00a0lives will not be routinely available on the NHS because it is too expensive. NICE (National Institute of\u00a0 Health Care and Excellence) has confirmed that Kadcyla, a drug\u00a0able to extend life expectancy by around six\u00a0months in patients with incurable breast cancer, will not be available for all suitable candidates in […]<\/p>\n","protected":false},"author":888008809,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2145],"tags":[2284,2282,1944,2283],"class_list":["post-3415","post","type-post","status-publish","format-standard","hentry","category-cancer","tag-cancer-drugs-fund","tag-kadcyla","tag-nice","tag-roche"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.medic8.com\/news\/wp-json\/wp\/v2\/posts\/3415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.medic8.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.medic8.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.medic8.com\/news\/wp-json\/wp\/v2\/users\/888008809"}],"replies":[{"embeddable":true,"href":"https:\/\/www.medic8.com\/news\/wp-json\/wp\/v2\/comments?post=3415"}],"version-history":[{"count":0,"href":"https:\/\/www.medic8.com\/news\/wp-json\/wp\/v2\/posts\/3415\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.medic8.com\/news\/wp-json\/wp\/v2\/media?parent=3415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.medic8.com\/news\/wp-json\/wp\/v2\/categories?post=3415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.medic8.com\/news\/wp-json\/wp\/v2\/tags?post=3415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}